行业新闻

原文：
IRVINE, Calif.--(BUSINESS WIRE)--Transcatheter heart valve company CardiAQ Valve Technologies (“CVT”), which is developing the world’s first self-conforming Resilient Seated Gate Valves and self-anchoring technology for Transcatheter Mitral Valve Implantation (TMVI), announced today that it has established operations in Irvine, Calif. The 8,500-square-foot operation is a state-of-the-art research, development and manufacturing facility—with microbiology, biochemical, tissue-handling fixation, and tissue-valve-production capabilities. It includes two GMP-certified ‘clean rooms’ for immediate pilot production capability of tissue valves and catheters. “CVT is also fortunate to have bolstered its core team with theAutomatic Control Valves addition of several former senior technical executives from CoreValve. We look forward to now rapidly moving toward the final stages of completing our proprietary designs of a novel pericardial mitral valve and its corresponding catheter for percutaneous delivery.” “While there is much work to be done, we are extremely pleased with the acceleration of our TMVI platform development since the completion of our Series A funding. We look forward to benefiting from the tremendous resources afforded to CVT by our recent move to this facility, which wasButterfly Valves occupied by CoreValve until just last year,” said Brent Ratz, CVT’s President and CEO. “CVT is also fortunate to have bolstered its core team with the addition of several former senior technical executives from CoreValve. We look forward to now rapidly moving toward the final stages of completing our proprietary designs of a novel pericardial mitral valve and its corresponding catheter for percutaneous delivery.” About CardiAQ Valve Technologies Privately held CVT, headquartered in Irvine, Calif., has developed a proprietary system for Transcatheter Mitral Valve Implantation (TMVI). Through the combination of a unique anchoringCheck Valves mechanism and a novel delivery catheter, physicians will be able to accurately and securely implant a new mitral valve within a beating heart, thus avoiding open-heart surgery. The CVT procedure is designed to be performed in a cardiac catheterization laboratory similar to angioplasty or stenting, resultingSafety Valves in less trauma to the patient and substantial cost-savings to the healthcare system
原文来自：http://www.nytimes.com/1996/02/16/nyregion/new-jersey-daily-briefing-valve-caused-pipes-to-burst.html

NEW JERSEY DAILY BRIEFING;Valve Caused Pipes to Burst;是由上海赛泰泵阀有限公司提供的阀门新闻，中文译文仅供参考，以下提供站内导航搜索：

中国针型阀网针型阀产品针型阀知识针型阀厂商针型阀博客针型阀行业新闻

以下是参考译文：

译文：阀门技术GMP认证
欧文，加利福尼亚州 - （商业新闻） - 经导管心脏电磁阀瓣膜公司CardiAQ阀门技术有限公司（“无级变速器”），这是发展中世界上第一个自我不合格和自我锚固导管二尖瓣植入（TMVI），技术今日它成立于尔湾，加利福尼亚州的8500平方英尺的经营业务是一个国家的最先进的研究，开发和制造的微生物，生化设施，，组织处理固定，组织阀生产的能力。它包括两个的GMP认证的'干净立即组织试点阀和导管生产能力房'。 “无级变速器还幸运地支撑与一些前高级技术管理人员从CoreValve除了核心团队。我们闸阀期待着正迅速朝着完成新型心包二尖瓣及其对我们的经皮导管交付相应的专利设计的最后阶段。“ “尽管还有许多工作要做，我们非常高兴与我们的TMVI平台的发展，因为我们截止阀的A系列资金加速完成。我们期待着从我们提供最近将这一设施，这是由CoreValve占领，直到去年才以无级变速器的巨大资源中受益，“布伦特说拉茨，无级变速器的总裁和首席执行官。 “无级变速器还幸运地支撑与一些前高级技术管理人员从CoreValve除了核心团队。我们期待着正迅速朝着完成新型心包二尖瓣及其对我们的经皮导管交付相应的专利设计疏水阀的最后阶段。“ 关于CardiAQ阀技术私人控股的无级变速器，在欧文，总部位于加利福尼亚州，已经制定了经导管呼吸阀二尖瓣植入（TMVI）专有系统。通过一个独特的锚固机制结合，提供了一种新的导管，医生们将能够准确，安全地跳动的心脏内植入一个新的二尖瓣，从而避免心脏直视手术。该平衡阀无级变速器程序的设计是在一个类似心导管实验室支架血管柱塞阀成形术或演出，在减少对病人造成的创伤，并大幅节约成本的医疗保健系统

更多新闻